The Burrill Report
The Burrill Report (August 12, 2013): Measuring Pharma Innovation (.MP3,25.87 Mb)
How well the pharmaceutical industry is doing at producing innovative drugs may depend in part on what and how you measure its output. A new study in the August issue of Health Affairs by staffers at the U.S. Food and Drug Administration suggests the industry might be doing better than some believe. We spoke to Michael Lanthier, operations research analyst on the FDA’s economics staff and lead author of the study, about what he found, the importance of looking beyond a simple count of new drug approvals, and why he finds encouraging signs in the data.
August 09, 2013